Adicet Bio
ACET
87 hedge funds and large institutions have $630M invested in Adicet Bio in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 22 reducing their positions, and 11 closing their positions.
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
45% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 22
25% more capital invested
Capital invested by funds: $504M → $630M (+$125M)
7% more funds holding
Funds holding: 81 → 87 (+6)
0.22% more ownership
Funds ownership: 4.97% → 5.19% (+0.22%)
13% less call options, than puts
Call options by funds: $1.76M | Put options by funds: $2.02M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$21.6M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.34M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.38M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$2.82M |
| 5 |
BlackRock
New York
|
+$2.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.83M |
| 2 |
Two Sigma Investments
New York
|
-$4.47M |
| 3 |
Walleye Capital
New York
|
-$3.63M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.62M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.52M |
ACET Hedge Fund Activity: Q1 2022 in Review
87 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q1 2022, worth a combined $630M — up 25% from $504M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ACET positions and 11 closed out — a net gain of 6 holders — while 32 added to existing stakes and 22 trimmed.
The largest buyer was Cowen and Company, opening a new position worth an estimated $21.6M. The largest seller was Point72 Asset Management, cutting an estimated $5.83M.
- 87 institutional investors held Adicet Bio (ACET) as of Q1 2022, up from 81 in Q4 2021.
- Funds reported $630M of Adicet Bio stock for Q1 2022, up 25% quarter-over-quarter.
- 17 funds opened new Adicet Bio positions in Q1 2022 and 11 closed out, a net change of +6 holders.
- The largest Adicet Bio buyer in Q1 2022 was Cowen and Company, an estimated $21.6M added.
- The largest Adicet Bio seller in Q1 2022 was Point72 Asset Management, an estimated $5.83M sold.
Based on aggregated 13F filings for Q1 2022.